CJC-1295 Research: Mechanism, Human Trials, and Structural Comparisons
CJC-1295 activates pituitary GHRH receptors via a Gαs/cAMP/PKA cascade. Two published human RCTs in n=24 healthy adults document dose-dependent GH elevation of 2–10-fold, sustained IGF-1 elevation for 9–11 days, and preserved GH pulsatility throughout.
Mechanism of Action: GHRH Receptor Signaling
CJC-1295 binds the GHRH receptor (GHRH-R), a Gαs-coupled receptor expressed on anterior pituitary somatotroph cells. Binding activates adenylyl cyclase, elevating intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates the transcription factor CREB, driving GH and GHRH-R gene expression; separately, PKA triggers voltage-dependent calcium-channel opening for acute GH exocytosis. MAPK and PI3K signaling pathways downstream mediate somatotroph proliferation.[12]
This cascade — the Gαs/cAMP/PKA/CREB axis — is the shared mechanism of all GHRH analogs, including sermorelin and tesamorelin. What distinguishes CJC-1295 from sermorelin is metabolic stability: four amino-acid substitutions (most critically, the substitution of alanine at position 2 with alpha-aminoisobutyric acid, Aib) block DPP-IV cleavage and extend plasma half-life from sermorelin's ~10–12 minutes to CJC-1295 no-DAC's ~30 minutes.[15] The DAC form extends this further to 5.8–8.1 days.[3]
CJC-1295 acts exclusively on the GH/IGF-1 axis. It does not directly engage the hypothalamic-pituitary-gonadal (HPG) axis; no direct testosterone effect has been demonstrated in published CJC-1295 trials.[19]
Human Clinical Evidence: The Two Published RCTs
Two randomized, placebo-controlled, double-blind trials constitute the complete published human evidence base for CJC-1295.
Enrolled healthy adult volunteers in an ascending-dose design (30, 60, 90, and 125 μg/kg SC). A single injection elevated mean plasma GH 2- to 10-fold dose-dependently, sustained for six days or more; IGF-1 rose 1.5- to 3-fold and remained elevated for nine to eleven days. Terminal half-life estimated at 5.8–8.1 days. No serious adverse reactions reported. Maximum trial duration: 49 days.[1]
Examined whether continuous GHRH-R stimulation would suppress endogenous GH pulsatility. At 60 and 90 μg/kg SC, trough GH rose 7.5-fold above baseline (P<0.0001) and mean GH rose 46%, but pulse frequency and amplitude remained intact — endogenous GH pulsatility was preserved.[2]
Total enrolled n across both studies: 24. Maximum trial duration: 49 days. No long-term (>3 months) human safety data exists. No published human pharmacokinetic study exists specifically for the no-DAC form (Mod GRF 1-29).
In GHRH-knockout mice, once-daily CJC-1295 at 2 μg/day SC over five weeks normalized body weight, tibial length, and GH mRNA levels compared to wild-type controls.[4]
CJC-1295 with DAC: Drug Affinity Complex
The DAC (Drug Affinity Complex) is a proprietary C-terminal extension on CJC-1295 that includes a maleimide-reactive group. After subcutaneous injection, the maleimide moiety forms a covalent thioether bond with the free thiol of Cys34 on circulating serum albumin. The resulting ~70 kDa albumin–peptide complex is too large for renal filtration and is shielded from further proteolysis — nearly piggy-backing on albumin's own 19-day plasma half-life. The result is a terminal half-life of 5.8–8.1 days for CJC-1295 with DAC, measured in the Teichman 2006 human trial.[1]
In the original characterization study by Jetté et al. (2005), the albumin bioconjugate produced a 4-fold increase in GH AUC over two hours versus unconjugated hGRF(1-29) in rats, and was still detectable in plasma at 72 hours.[3] The downstream GH profile of the with-DAC form is tonic — sustained basal GH elevation — rather than discrete physiologic pulses. Endogenous pulses remain measurable (Ionescu 2006 confirmed this[2]), but the pulsatile amplitude ratio shifts toward a higher baseline.
Mod GRF 1-29: CJC-1295 Without DAC
Mod GRF 1-29 is the no-DAC version of CJC-1295. The two names — 'CJC-1295 no DAC,' 'Modified GRF 1-29,' and 'Mod GRF 1-29' — refer to the same molecule: the 29-residue GHRH backbone with four DPP-IV-stabilizing substitutions, lacking the albumin-binding DAC C-terminus.
Without the DAC extension the plasma half-life is approximately 30 minutes, derived from the DPP-IV resistance conferred by the four backbone substitutions.[15] This short half-life means the no-DAC form produces a discrete, physiologically pulsatile GH response rather than the tonic elevation produced by the with-DAC form.
No published human pharmacokinetic study exists specifically for Mod GRF 1-29 / CJC-1295 no DAC. The ~30-minute half-life estimate is derived from structural analysis and in vitro DPP-IV resistance data.[3]
CJC-1295 vs Sermorelin: Structural and Activity Differences
Sermorelin is a truncated native GHRH(1-29) analog with unmodified amino acids and a plasma half-life of approximately 10–12 minutes. DPP-IV cleaves the N-terminal Tyr-Ala bond rapidly, inactivating the molecule. CJC-1295 introduces four substitutions — most critically, alpha-aminoisobutyric acid (Aib) at position 2, the primary DPP-IV cleavage site — that resist this inactivation and extend the no-DAC half-life to approximately 30 minutes.[15]
| Compound | Half-Life | Mechanism of Clearance |
|---|---|---|
| Sermorelin (GHRH(1-29)) | ~10–12 min | DPP-IV cleavage at Tyr-Ala |
| CJC-1295 no DAC (Mod GRF 1-29) | ~30 min | DPP-IV resistant; proteolysis + renal filtration |
| CJC-1295 with DAC | 5.8–8.1 days | Albumin-bound (~70 kDa); shielded from proteolysis |
Both sermorelin and CJC-1295 act at the same GHRH-R via the same Gαs/cAMP/PKA cascade. No head-to-head clinical efficacy trial comparing sermorelin and CJC-1295 exists in the published literature. Sermorelin holds an FDA-approval history (approved, then withdrawn for non-safety reasons). CJC-1295 does not.
CJC-1295 and Hormonal Axes
CJC-1295 acts on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal (HPG) axis directly. The GHRH receptor is expressed on pituitary somatotrophs, not gonadotrophs. No peer-reviewed study documents direct testosterone elevation from CJC-1295 administration; the Teichman 2006 and Ionescu 2006 studies measured GH and IGF-1 exclusively and did not assess LH, FSH, or testosterone.[19]
Oral Bioavailability: Why CJC-1295 Requires Injectable Administration
CJC-1295 has a molecular weight of approximately 3,647 Da. Peptides of this size are degraded by gastrointestinal proteases — notably pepsin, trypsin, and chymotrypsin — before reaching systemic circulation; no oral bioavailability has been documented for CJC-1295 in any published study.[17] All published human and rodent studies use subcutaneous injection.
CJC-1295 vs Exogenous HGH: Mechanism and Research Context
CJC-1295 stimulates endogenous GH production at the pituitary, preserving negative feedback via somatostatin and the GH/IGF-1 axis. Endogenous GH pulses persist and remain measurable during CJC-1295 administration;[2] post-study GH suppression has not been reported in published trials.[18] Exogenous synthetic GH bypasses this regulatory architecture — it delivers GH directly, suppressing pituitary output via somatostatin entrainment and negative IGF-1 feedback.
No head-to-head clinical efficacy trial comparing CJC-1295 with exogenous GH exists in the published literature. Exogenous GH has several approved human indications; CJC-1295 does not.